BioCentury | Aug 5, 2017
Regulation

Enabling efficiency in TB

...from real-time decisions being informed by real-time assessment of efficacy during the trial," said Hanna. Sequella Inc....
...day or two. It takes weeks, if not months, to get the answer for TB." Sequella’s...
...Frontières (MSF), Geneva, Switzerland Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Sequella Inc....
BioCentury | Apr 21, 2017
Clinical News

SQ109: Ph IIb/III data

...plus standard therapy (80% vs. 61%). SQ109 was well tolerated. In 2006, the NIH granted Sequella...
...Independent States under a 2011 deal between Russian financial firm Maxwell Biotech Venture Fund and Sequella...
...2, 2011 ). Infectex is a portfolio company of Maxwell. Infectex Ltd. , Moscow, Russia Sequella Inc....
BioCentury | Jul 22, 2013
Company News

Sequella, Pfizer deal

...Pfizer granted Sequella exclusive, worldwide rights to develop and commercialize the pharma's sutezolid, which is in...
...and commercialize the pharma's sutezolid, which is in Phase II testing to treat tuberculosis (TB). Sequella...
...by year end. Sequella said the financing will fund pivotal trials for sutezolid and SQ109. Sequella Inc....
BioCentury | Jul 18, 2013
Company News

Pfizer licenses TB compound to Sequella

...Pfizer Inc. (NYSE:PFE) granted anti-infectives company Sequella Inc. (Rockville, Md.) exclusive, worldwide rights to develop and commercialize...
...and commercialize the pharma's sutezolid, which is in Phase II testing to treat tuberculosis (TB). Sequella...
...anti-bacterials and is seeking to license its remaining early stage programs in the space. Separately, Sequella...
BioCentury | Oct 29, 2012
Company News

Sequella, LabCorp deal

...will combine nucleic acid testing with phage-based technology to identify antibiotic resistance in M. tuberculosis. Sequella...
...ex-US territories. B-SMART technology enables nucleic acid-based systems to measure bacterial viability and drug resistance. Sequella...
...declined to provide details, including financial terms, while LabCorp could not be reached for comments. Sequella Inc....
BioCentury | May 21, 2012
Finance

Sweetening the pot

...entities that invest at least $25,000 in a qualified Maryland biotech. Investors in anti-infectives play Sequella Inc....
BioCentury | May 2, 2011
Company News

Sequella deal

...tuberculosis (TB) candidate SQ109 in Russia and the Commonwealth of Independent States. Under the deal, Sequella...
...Further terms were not disclosed. In 2006, the National Institutes of Health (Bethesda, Md.) granted Sequella...
...Sequella's funding under the 2006 deal (see BioCentury, April 10, 2006 & Nov. 23, 2009). Sequella Inc....
BioCentury | Oct 25, 2010
Clinical News

SQ109: Phase IIa start

...By year end, Sequella will begin an open-label, African Phase IIa trial in 90 patients to...
...in the U.S. and EU, and Fast Track designation in the U.S. to treat TB. Sequella Inc....
BioCentury | Sep 6, 2010
Company News

Sequella, University of Maryland deal

...a labeled pill to monitor drug compliance. Sequella and the university jointly discovered the technology. Sequella...
...responsible for development and the university is eligible for milestones. Further terms were not disclosed. Sequella Inc....
BioCentury | Aug 2, 2010
Clinical News

J&J preclinical data

...to the rate for each compound alone. Data were published in Antimicrobial Agents and Chemotherapy. Sequella Inc....
Items per page:
1 - 10 of 34
BioCentury | Aug 5, 2017
Regulation

Enabling efficiency in TB

...from real-time decisions being informed by real-time assessment of efficacy during the trial," said Hanna. Sequella Inc....
...day or two. It takes weeks, if not months, to get the answer for TB." Sequella’s...
...Frontières (MSF), Geneva, Switzerland Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Sequella Inc....
BioCentury | Apr 21, 2017
Clinical News

SQ109: Ph IIb/III data

...plus standard therapy (80% vs. 61%). SQ109 was well tolerated. In 2006, the NIH granted Sequella...
...Independent States under a 2011 deal between Russian financial firm Maxwell Biotech Venture Fund and Sequella...
...2, 2011 ). Infectex is a portfolio company of Maxwell. Infectex Ltd. , Moscow, Russia Sequella Inc....
BioCentury | Jul 22, 2013
Company News

Sequella, Pfizer deal

...Pfizer granted Sequella exclusive, worldwide rights to develop and commercialize the pharma's sutezolid, which is in...
...and commercialize the pharma's sutezolid, which is in Phase II testing to treat tuberculosis (TB). Sequella...
...by year end. Sequella said the financing will fund pivotal trials for sutezolid and SQ109. Sequella Inc....
BioCentury | Jul 18, 2013
Company News

Pfizer licenses TB compound to Sequella

...Pfizer Inc. (NYSE:PFE) granted anti-infectives company Sequella Inc. (Rockville, Md.) exclusive, worldwide rights to develop and commercialize...
...and commercialize the pharma's sutezolid, which is in Phase II testing to treat tuberculosis (TB). Sequella...
...anti-bacterials and is seeking to license its remaining early stage programs in the space. Separately, Sequella...
BioCentury | Oct 29, 2012
Company News

Sequella, LabCorp deal

...will combine nucleic acid testing with phage-based technology to identify antibiotic resistance in M. tuberculosis. Sequella...
...ex-US territories. B-SMART technology enables nucleic acid-based systems to measure bacterial viability and drug resistance. Sequella...
...declined to provide details, including financial terms, while LabCorp could not be reached for comments. Sequella Inc....
BioCentury | May 21, 2012
Finance

Sweetening the pot

...entities that invest at least $25,000 in a qualified Maryland biotech. Investors in anti-infectives play Sequella Inc....
BioCentury | May 2, 2011
Company News

Sequella deal

...tuberculosis (TB) candidate SQ109 in Russia and the Commonwealth of Independent States. Under the deal, Sequella...
...Further terms were not disclosed. In 2006, the National Institutes of Health (Bethesda, Md.) granted Sequella...
...Sequella's funding under the 2006 deal (see BioCentury, April 10, 2006 & Nov. 23, 2009). Sequella Inc....
BioCentury | Oct 25, 2010
Clinical News

SQ109: Phase IIa start

...By year end, Sequella will begin an open-label, African Phase IIa trial in 90 patients to...
...in the U.S. and EU, and Fast Track designation in the U.S. to treat TB. Sequella Inc....
BioCentury | Sep 6, 2010
Company News

Sequella, University of Maryland deal

...a labeled pill to monitor drug compliance. Sequella and the university jointly discovered the technology. Sequella...
...responsible for development and the university is eligible for milestones. Further terms were not disclosed. Sequella Inc....
BioCentury | Aug 2, 2010
Clinical News

J&J preclinical data

...to the rate for each compound alone. Data were published in Antimicrobial Agents and Chemotherapy. Sequella Inc....
Items per page:
1 - 10 of 34